Understanding Insurance Coverage & Cost-Share Assistance with Marissa Shackleton

April 29, 2020

What Infusion Operators Should Know about Medically Integrated Dispensing

November 17, 2026

NICA Response to CMS’ Request for Information on the Essential Health Benefits Framework

July 15, 2026

Regulatory Comment

In July 2026, NICA submitted comments on the Centers for Medicare & Medicaid Services’ (CMS) review of the Essential Health Benefits (EHB) framework. NICA highlighted concerns about alternative funding programs that exclude medically necessary specialty medications from insurance coverage, copay accumulator and maximizer programs, and inadequate protections for provider-administered therapies. NICA urged CMS to strengthen coverage standards and ensure meaningful patient access to specialty medications.


July 15, 2026

Mehmet Oz, MD, MBA

Administrator

Centers for Medicare and Medicaid Services

200 Independence Avenue, SW

Washington, DC 20201

Submitted electronically via www.regulations.gov 

Re: Request for Information; Comprehensive Review of the Essential Health Benefits Framework and Typical Employer Plan Standard (CMS–9874–NC)

Dear Administrator Oz:

The National Infusion Center Association (NICA) is a nonprofit organization formed to support non- hospital, community-based infusion centers caring for patients in need of provider-administered medications. To improve access to medical benefit drugs that treat complex, rare, and chronic diseases, we work to ensure that patients can access these drugs in safe, more efficient, and cost-effective alternatives to hospital care settings. NICA supports policies that improve drug affordability for beneficiaries, increase price transparency, reduce disparities in safety across care settings, and foster patient access to the highest-quality, lowest-cost setting.

Today, we write to provide feedback on relevant questions in the aforementioned RFI. Although NICA’s comments primarily address Topics 3 through 5, the agency’s questions regarding the definition of a “typical employer plan” in Topic 1 are directly relevant to the concerns discussed below.

Topic 3: Affordability and Cost
Responses to Questions 3.1 – 3.5

NICA recognizes that specialty medications, including many provider-administered therapies used to treat chronic, rare, and complex conditions, contribute to increased healthcare spending and insurance premiums. However, these therapies are medically necessary and often represent the standard of care, preventing disease progression, avoidable hospitalizations and complications, permanent disability, diminished quality of life, and ultimately even higher healthcare costs.

In response to these costs, plans increasingly rely on benefit designs intended to control specialty drug spending. These include utilization management tools, such as prior authorization and step therapy, that delay or restrict access to treatment; formulary designs that may prioritize higher-cost medications with larger manufacturer rebates over lower-cost clinically appropriate alternatives, increasing patient cost-sharing and limiting access; and copay adjustment programs, such as copay accumulator and copay maximizer programs, that increase patients’ out-of-pocket costs and make therapies less affordable and accessible.

NICA is particularly concerned about the growing use of alternative funding programs (AFPs) by large group and self-funded employer-sponsored health plans. Unlike traditional utilization management or cost-sharing strategies, health plans eliminate coverage for certain specialty medications by designating them as “non-essential health benefits” and use AFPs to redirect insured patients to manufacturer patient assistance programs (PAPs), charities, or third-party funding sources. In effect, patients are deceptively treated as though they are uninsured for a medication simply because their health plan has chosen not to provide coverage.

In addition, because these medications are excluded from plan coverage, payments made through manufacturer PAPs, charities, or third-parties or by patients themselves generally do not count toward the patient’s cost-sharing obligations under the health plan (e.g., deductible, out-of-pocket maximums), leaving them financially exposed if they later require other covered medical care or their manufacturer patient assistance is exhausted.

Further, patients may spend weeks navigating assistance eligibility requirements before learning whether support is available, delaying treatment and disrupting continuity of care. If assistance is unavailable, patients may be left with few options other than changing health plans during a future enrollment period in hopes of obtaining coverage for the therapy they need.

These practices – known as the “EHB loophole” – prompted NICA and several like-minded stakeholders to call on the Departments of Labor (DOL) and Treasury to issue a promised regulation addressing the use of “non-essential health benefit” designations in large group and self-funded employer-sponsored health plans. Until those regulations are finalized, CMS has an independent responsibility to appropriately define and implement the EHB framework for Affordable Care Act (ACA) and other plans subject to EHB requirements. As CMS reexamines the definition of a “typical employer plan” through this RFI, the agency should ensure that employer benefit design practices that eliminate coverage for medically necessary provider-administered therapies, including through alternative funding arrangements, are not used to inform its interpretation of what constitutes a typical employer plan simply because they have become more common in the employer market.

Topic 4: Scope of Benefits Included as EHB
Responses to Questions 4.2 – 4.5

As CMS evaluates prescription drug coverage within the EHB framework, NICA encourages the agency to consider not only whether required drug categories and classes are represented within an EHB-benchmark plan, but also whether patients have meaningful access to clinically appropriate specialty medications. CMS’s current methodology appropriately evaluates pharmacy benefit coverage through benchmark formularies and therapeutic drug categories and classes. However, many specialty medications used to treat chronic, rare, and complex conditions are provider-administered therapies covered under the medical benefit. As a result, evaluating whether a therapeutic class is represented within a formulary does not necessarily demonstrate whether patients can access the infused and injectable therapies they need.

To address this, NICA urges CMS to supplement its current methodology with a comparable framework for evaluating provider-administered therapies covered under the medical benefit. This evaluation should consider whether coverage aligns with current clinical guidelines and evidence-based practice, reflects the scope of prescription drug coverage typically available under employer-sponsored plans, and accounts for the impact of utilization management, cost-sharing, reimbursement policies, coverage exclusions, site-of-care requirements, and other medical benefit design features that may limit patient access despite nominal coverage.

For many patients with chronic, rare, and complex conditions, provider-administered therapies are the standard of care and are essential to preventing disease progression, avoiding hospitalizations and complications, preserving function, and improving quality of life. Evaluating specialty medications covered under both the pharmacy and medical benefits using comparable methodologies will better ensure that EHB reflects current standards of care, supports effective chronic disease management, improves patient outcomes, and remains consistent with the ACA’s requirement that EHB be equal in scope to the benefits provided under a typical employer plan.

Topic 5: Updating EHB
Question 5.2 (EHB Safeguards)

As CMS considers potential updates to the EHB framework, the agency should establish safeguards that ensure plans provide meaningful coverage of medically necessary therapies and do not circumvent EHB requirements through benefit designs that effectively eliminate coverage for high-cost specialty medications.

First, CMS should clarify through future rulemaking that plans subject to EHB requirements may not satisfy prescription drug coverage requirements while excluding covered specialty medications through alternative funding arrangements. Patients should not be forced to rely on charitable assistance simply because their health plan has chosen not to cover a prescribed therapy. Patient assistance programs exist to help patients who are truly uninsured or underinsured – not to allow insurers, employers, and their pharmacy benefit managers to avoid covering medically necessary therapies while shifting the financial burden elsewhere.

Second, CMS must address the continued use of copay accumulator and copay maximizer programs in plans subject to EHB requirements. Despite years of rulemaking and litigation regarding the treatment of manufacturer copay assistance, many patients continue to face increased out-of-pocket costs because manufacturer copay assistance often does not count toward their deductible or annual out-of-pocket maximum. In many cases, this leads patients to delay or abandon care. The absence of a clear and consistent federal policy has resulted in uneven patient protections and continued uncertainty. NICA urges CMS to restore the policy finalized in the 2020 Notice of Benefit and Payment Parameters requiring manufacturer assistance for EHB drugs to count toward a patient’s cost-sharing obligations unless a medically appropriate generic equivalent is available.

Finally, CMS should ensure that future evaluations of EHB prescription drug coverage assess meaningful patient access to specialty medications covered under both the pharmacy and medical benefits. Plans should not be considered to provide meaningful prescription drug coverage simply because a drug category or therapeutic class is represented if patients cannot reasonably access clinically appropriate provider-administered therapies through the medical benefit.

***

Thank you for the opportunity to comment on these important issues. We would welcome the opportunity to connect with you if we can provide any other information about our concerns. Please do not hesitate to contact me, should you have any questions or wish to further discuss these issue: [email protected]

Sincerely,

Brian Nyquist, MPH Chief Executive Officer

National Infusion Center Association

Related Posts

August 4, 2026

NICA Comments on CMS Proposed Rule Regarding the Medicare Drug Price Negotiation Program for IPAY 2029

In August 2026, NICA submitted comments to the Centers for Medicare & Medicaid Services (CMS) on proposed changes to the Medicare Drug Price Negotiation Program. NICA […]
March 13, 2026

NICA Comments on CMS’ Proposed 2027 Notice of Benefit and Payment Parameters

In March 2026, NICA submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed 2027 Notice of Benefit and Payment Parameters (NBPP). […]
February 20, 2026

NICA Comments on CMS’ Proposed Global Benchmark for Efficient Drug Pricing (GLOBE) Model

In February 2026, NICA submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed GLOBE Model for Medicare Part B drug pricing. […]
✕

Login

When you login, you will be directed to admin.infusioncenter.org. When you get there:

  • Enter the email address that was used to claim your center in the Infusion Center Locator or
  • If you are looking to add your infusion center (i.e. it does not already exist as an unclaimed location in the locator), enter the email you would like to be associated with the location.

You will receive an email with a link to click that will log you into the resources section of the locator, which includes your claimed and/or activated infusion center(s).

Please note: you will have to enter your email each time as we no longer have passwords for extra security. This login process is separate from the forum.

If you have questions about the email address associated with the location, how to add or claim a center, how to purchase a resource, etc., please email our Member Relations lead, Ashley Kana at [email protected].

✕

NICA